GSK Flovent/Advair Diskus Needs More COPD Data; Serevent Cleared For COPD
Executive Summary
FDA is seeking additional efficacy data on GlaxoSmithKline's Flovent Diskus and Advair Diskus for chronic obstructive pulmonary disease before approving the products for the supplementary indication